As of 2025-05-26, the EV/EBITDA ratio of Xilio Therapeutics Inc (XLO) is 0.17. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. XLO's latest enterprise value is -9.53 mil USD. XLO's TTM EBITDA according to its financial statements is -55.56 mil USD. Dividing these 2 quantities gives us the above XLO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.1x - 13.4x | 13.3x |
| Forward P/E multiples | 16.5x - 30.5x | 19.0x |
| Fair Price | (16.66) - (13.29) | (16.26) |
| Upside | -1984.8% - -1603.6% | -1939.9% |
| Date | EV/EBITDA |
| 2025-05-23 | 0.19 |
| 2025-05-22 | 0.16 |
| 2025-05-21 | 0.22 |
| 2025-05-20 | 0.16 |
| 2025-05-19 | 0.18 |
| 2025-05-16 | 0.19 |
| 2025-05-15 | 0.25 |
| 2025-05-14 | 0.20 |
| 2025-05-13 | -0.08 |
| 2025-05-12 | 0.31 |
| 2025-05-09 | 0.33 |
| 2025-05-08 | 0.32 |
| 2025-05-07 | 0.37 |
| 2025-05-06 | 0.35 |
| 2025-05-05 | 0.31 |
| 2025-05-02 | 0.30 |
| 2025-05-01 | 0.29 |
| 2025-04-30 | 0.28 |
| 2025-04-29 | 0.29 |
| 2025-04-28 | 0.26 |
| 2025-04-25 | 0.22 |
| 2025-04-24 | 0.21 |
| 2025-04-23 | 0.26 |
| 2025-04-22 | 0.24 |
| 2025-04-21 | 0.24 |
| 2025-04-17 | 0.29 |
| 2025-04-16 | 0.29 |
| 2025-04-15 | 0.33 |
| 2025-04-14 | 0.33 |
| 2025-04-11 | 0.33 |
| 2025-04-10 | 0.38 |
| 2025-04-09 | 0.36 |
| 2025-04-08 | 0.39 |
| 2025-04-07 | 0.37 |
| 2025-04-04 | 0.36 |
| 2025-04-03 | 0.34 |
| 2025-04-02 | 0.31 |
| 2025-04-01 | 0.36 |
| 2025-03-31 | 0.32 |
| 2025-03-28 | 0.30 |
| 2025-03-27 | 0.31 |
| 2025-03-26 | 0.31 |
| 2025-03-25 | 0.29 |
| 2025-03-24 | 0.26 |
| 2025-03-21 | 0.26 |
| 2025-03-20 | 0.26 |
| 2025-03-19 | 0.26 |
| 2025-03-18 | 0.27 |
| 2025-03-17 | 0.24 |
| 2025-03-14 | 0.25 |